Study aim: Determining the effect of melatonin with N-acetylcysteine in reducing liver damage caused by Ramdesivir injection in AJA staff with Covid 19 in Tehran hospitals in 2022 Design: A clinical trial with a control group, with parallel groups, double-blind, randomized, phase 4 on 80 patients, which used a random number table for randomization. Settings and conduct: The subjects will be selected from the AJA staff with Covid 19 disease in Tehran hospitals in 2022 who meet the inclusion criteria to reach the desired sample size. Then Patients are divided into two random groups that are matched in terms of age and sex. The intervention group received 6 mg of melatonin at bedtime and 600 mg of acetylcysteine during hospitalization, and the control group received a placebo at the same time with a similar appearance. All patients will be screened for AST and ALT at the time of admission serially until discharge, as well as underlying variables including age, sex and disease severity . It is noteworthy that during this period, patients and researchers will be unaware of the type of drug prescribed. Participants/Inclusion and exclusion criteria: Hospitalization indication of Covid 19 patient Indication for Remdesivir injection Patient satisfaction to participate in this research project Patients over 18 years old Presence of underlying liver disease in the patient Inability to receive oral durg Intervention groups: The intervention group received 6 mg of melatonin at bedtime and 600 mg of n-acetylcysteine during hospitalization, and the control group received a placebo with the same appearance at the same time. Main outcome variables: The effect of melatonin and N-acetylcysteine in reducing liver damage caused by remedisovir injection